Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe
United States United Kingdom Richard Paulson Elcin Barker Ergun Selective Inhibitor Of Nuclear Export Karyopharm Therapeutics Inc
Source: adnkronos.com